eltrombopag
UkraineDrugs containing this active substance
-
The drug is used to treat adults and children (from 1 year of age) with chronic immune (idiopathic) thrombocytopenic purpura (ITP) that is unresponsive to other treatments. It is also prescribed for the treatment of thrombocytopenia in patients with chronic hepatitis C and adults with severe aplastic anemia.
Form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg ATC: B02BX05
Manufacturer: Hetero Labs Limited
-
The drug is used to treat adults and children (from 1 year of age) with chronic immune (idiopathic) thrombocytopenic purpura (ITP) that is unresponsive to other treatments. It is also prescribed for the treatment of thrombocytopenia in patients with chronic hepatitis C and for adults with severe aplastic anemia.
Form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg ATC: B02BX05
Manufacturer: Hetero Labs Limited
-
The drug is used for the treatment of adults and children (from 1 year of age) with chronic immune (idiopathic) thrombocytopenia that is unresponsive to other treatments. It is also prescribed to adults for the treatment of thrombocytopenia associated with chronic hepatitis C and to adults with severe aplastic anemia.
Form: tablets, film-coated
Active substance Dosage eltrombopag 75 mg ATC: B02BX05
Manufacturer: Hetero Labs Limited
-
The drug is used to treat adults and children (from 1 year of age) with chronic immune thrombocytopenic purpura that has not responded to other treatments. It is also prescribed for the treatment of thrombocytopenia in chronic hepatitis C and for adults with severe aplastic anemia.
Form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg ATC: B02BX05
Manufacturer: Synthon Hispania, S.L. (batch release, manufacturing, primary, secondary packaging, batch control)
-
The drug is used to treat adults and children (from 1 year of age) with chronic immune thrombocytopenic purpura that is unresponsive to other treatments. It is also prescribed for the treatment of thrombocytopenia in chronic hepatitis C and for adults with severe aplastic anemia.
Form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg ATC: B02BX05
Manufacturer: Synthon Hispania, S.L. (batch release, manufacturing, primary, secondary packaging, batch control)
-
The drug is used for the treatment of patients with chronic immune (idiopathic) thrombocytopenic purpura (aged 1 year and older), thrombocytopenia in adults with chronic hepatitis C, as well as for the treatment of adults with severe aplastic anemia.
Form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg ATC: B02BX05
Manufacturer: Glaxo Operations UK Ltd (manufacturing, quality control)
-
The drug is used for the treatment of patients with chronic immune (idiopathic) thrombocytopenic purpura (aged 1 year and older), thrombocytopenia in adults with chronic hepatitis C, as well as for the treatment of adults with severe aplastic anemia.
Form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg ATC: B02BX05
Manufacturer: Glaxo Operations UK Ltd (manufacturing, quality control)